Currently ongoing clinical studies for BC are not available, although some promising preclinical studies have emerged, particularly in the context of TNBC: EPZ-6438 treatment significantly reduced H3K27me3 levels, increased ERα expression in TNBC cell lines, and promoted inhibition of cell growth and sensitivity to tamoxifen in murine models [200]. This evidence concerns the gene ESR1 and breast cancer.